News
The combined HER2 targeted therapy without chemotherapy
In a report that appears online in the Journal of Clinical Oncology, the researchers have shown that a subset of breast cancer patients who have tumors overexpressing a protein called the human epidermal growth factor receptor 2 (HER-2...
News
Study reveals that chemotherapy works in an unexpected way
It's generally thought that anticancer chemotherapies work like antibiotics do, by directly killing off what's harmful. But new research published online on April 4 in the Cell Press journal Immunity shows that effective chemotherapies actually work by mobilizing...
News
New relief for gynecological disorders
The creation of new blood vessels in the body, called "angiogenesis," is usually discussed in connection with healing wounds and tumors. But it's also an ongoing process in the female reproductive tract, where the...
News
New nanomedicine resolves inflammation, promotes tissue healing
A multicenter team of researchers, including scientists at Columbia University Medical Center (CUMC), Brigham and Women's Hospital (BWH), Mount Sinai School of Medicine, and Massachusetts Institute of Technology, has developed biodegradable nanoparticles that are capable of delivering inflammation-resolving...
News
Newly approved blood thinner may increase susceptibility to some viral infections
A study led by researchers at the University of North Carolina indicates that a newly approved blood thinner that blocks a key component of the human blood clotting system may increase the risk and severity of certain viral...
News
Genetic ‘spelling mistakes’ that increase the risk of common cancers
More than 80 genetic 'spelling mistakes' that can increase the risk of breast, prostate and ovarian cancer have been found in a large, international research study within the framework of the EU Network COGS. ...
News
FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa
A new perspective from the U.S. Food and Drug Administration (FDA) published in the New England Journal of Medicine states that the agency has not changed its recommendations regarding Pradaxa® (dabigatran etexilate), following the November 2012 Mini-Sentinel evaluations....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read